glp 1 novo nordisk products inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs McKee's proposed FY2027 budget drops
Description
Not only have the molecules remained on the market, utilization is increasing, suggesting that some pharmacies may be leveraging formulation additives or alternative delivery mechanisms to justify continued production
Discover how low dose GLP-1 medications may reduce inflammation through novel mechanisms
Constipation is one of the most common side effects of GLP-1 agonist medications
PlexusDx compounded semaglutide and tirzepatide injections are HSA and FSA eligible, making precision weight loss therapy more accessible to patients managing obesity
